肝癌、肺癌、胃癌患者血清GST-π含量的测定及其临床意义

Determination of Serum GST-π in Patients with hepatoma, Lung and Gastric Carcinomas and Its Clinical signification

采用Guesdon法制备出生物素化兔抗人GST-π抗体(B-IgG)。以生物素-亲和素-酶联免疫吸附试验(BA-ELISA)测定了肝癌、肺癌、胃癌患者血清和胎儿脐带血血清中的GST-π含量。测定结果,肝癌、肺癌、胃癌患者血清中GST-π含量分别为7.25±6.47ng/ml,4.3±1.85ng/ml,3.74±2.25ng/ml,比正常人的1.16+0.81ng/ml均显著升高,胎儿脐带血血清中GST-π含量为1.14±0.88ng/ml,与正常人相比无明显差异。故认为,血清中GST-π很有可能成为肝癌、肺癌、胃癌的一个肿瘤标志。

The Biotin-labeled anti-GST-π antibody was obtained by a procedure described by Guesdon et al. The GST-π in serum was determined using biotin-avidin enzyme-linked immunosorbent ashy. The serum GST-π concentrations were 7.25±4-6.47ng/ml, 4.3±1.85ng/ml, 3.74±2.25ng/ml in patients with hepatoma, lung and gastric carcinomas, respectivily, they were all significantly higher than normal controls (1.16±0.81 ng/ml). The results appear that the serum GST-π contents might be a tumor marker for the patients with these carcinomas. The serum GST-π of fetal umbilical cord was also determined (1.14±0.88ng/ml), showing no difference compared with normal controls.